Phase III trial of ublituximab in combination with TGR 1202 in patients with indolent non-Hodgkin's lymphoma
Phase of Trial: Phase III
Latest Information Update: 15 Jun 2017
At a glance
- Drugs Ublituximab (Primary) ; Umbralisib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms UNITY-iNHL
- 15 Jun 2017 According to TG Therapeutics media release, the company is planning to add Triple Combination of TG-1101, TGR-1202, and Bendamustine in DLBCL arm in UNITY-NHL program and enroll patients into this cohort before the end of the summer 2017.
- 10 May 2016 The company is planning to initiate this trial before end of the year 2016, as reported in a TG Therapeutics media release.
- 19 Jan 2016 Planned initiation date changed from 1 Jul 2015 to 1 Jul 2016, as per a TG Therapeutics Inc media release.